Loading organizations...
Founded in 2013 by Feyi Olopade Ayodele, Haibo Lu, and Olufunmilayo Olopade, CancerIQ develops a healthcare software platform that utilizes genetic data to assist medical providers in identifying vulnerable patients and preventing cancer through personalized care plans. Based in Chicago, the company operates a SaaS business model that automates clinical workflows and streamlines genetic counseling for oncology departments across more than 200 medical locations. The enterprise generates an estimated $8.7 million in annual revenue, has secured $14 million in funding, holds an estimated $27.9 million valuation, and maintains 21 to 50 employees. CancerIQ currently supports approximately 40,000 active platform users and recently increased its investment in specialized tools designed for the genetic counseling community. The corporate leadership team includes key figures like Director of Engineering Melissa Netto and Director of Business Development Kat Kostolansky.
CancerIQ has raised $19.0M across 2 funding rounds.
CancerIQ has raised $19.0M in total across 2 funding rounds.
CancerIQ is a healthcare technology company that builds a precision oncology platform to enable cancer prevention and early detection at scale. It provides tools for risk assessment, genetic testing, patient navigation, care plan management, and analytics, integrating seamlessly with electronic health records (EHRs) to serve health systems, oncology teams, primary care, radiology, genetics, and navigation services.[1][2][3][4] The platform identifies patients at high risk based on genetic, family history, lifestyle, and other factors using science-based models like Tyrer-Cuzick, automates workflows, delivers personalized education, and connects to telehealth genetic counseling, ultimately improving clinical outcomes, adherence to guidelines, and financial performance through revenue tracking.[1][3][4] Serving providers across ambulatory practices and digital health, CancerIQ demonstrates strong growth, with adoption in over 200 clinical locations nationwide and proven pilots screening tens of thousands of patients.[5][9]
CancerIQ was founded in 2013 in Chicago, Illinois, emerging from the MATTER startup accelerator as a solution to scale cancer risk assessment beyond manual pedigree tools.[2][5] Early traction came from a 2015 pilot with OSF HealthCare in Peoria, where a simple five-minute online survey screened over 20,000 women for breast cancer risk, identifying more than 5,000 at high hereditary risk and leading to expansion across OSF facilities by 2017, with additional screenings of 14,000 patients and 25 confirmed genetic mutations.[5] This grassroots validation evolved the platform into a comprehensive intelligence solution, now powered by healthcare's largest precision prevention dataset, celebrating 10 years in 2023 with nationwide deployment.[3][9]
CancerIQ rides the precision medicine wave, capitalizing on genomics advancements and EHR interoperability to shift cancer care from reactive treatment to proactive prevention amid rising hereditary cancer burdens.[1][2][3] Timing aligns with NCCN guideline evolutions, AI-driven risk models, and telehealth expansion post-pandemic, enabling health systems to address workforce shortages by automating genetics expertise and scaling programs without added staff.[3][4][9] Market forces like value-based care and revenue optimization favor it, as downstream tracking ties risk programs to financial gains; it influences the ecosystem by standardizing precision oncology workflows, much like Canvas Medical does for EHRs, and inspires competitors in oncology tech.[1][2][4]
CancerIQ is poised to expand its platform with AI enhancements for even faster risk triaging and broader multi-omics integration, targeting more health systems amid genomics cost drops and regulatory pushes for preventive screening. Trends like FHIR APIs, personalized medicine mandates, and oncology workforce gaps will accelerate adoption, potentially doubling its 200+ locations footprint. Its influence may evolve from pilot innovator to ecosystem leader, powering population-level cancer risk reduction and redefining health systems' competitive edge in precision health.
CancerIQ has raised $19.0M across 2 funding rounds. Most recently, it raised $14.0M Series B in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $14M Series B | Amgen Ventures, Joel Krikston | 1776, HealthX Ventures, McKesson Ventures, OSF Ventures | Announced |
| Aug 1, 2020 | $5M Series A | HealthX Ventures | — | Announced |
CancerIQ has raised $19.0M in total across 2 funding rounds.
CancerIQ's investors include Amgen Ventures, Joel Krikston, 1776, HealthX Ventures, McKesson Ventures, OSF Ventures.
